What is the Role of Chemotherapy in Endometrial Cancer?
(2011) In Current Oncology Reports 13. p.433-441- Abstract
- Adjuvant pelvic radiotherapy has the potential to eradicate micrometastases within the irradiated field but has not resulted in survival improvements in randomized studies. This illustrates the need for systemic therapy. Chemotherapy, mainly with anthracyclines, platinum compounds, and taxanes, renders high response rates although this unfortunately translates in only modest improvements in progression-free and overall survival. Better systemic treatments need to be developed. Investigations of the molecular mechanisms of endometrial cancer have identified possible targets for therapy. In advanced endometrial cancer one study shows that chemotherapy is better than whole abdominal radiotherapy, while in the adjuvant situation the... (More)
- Adjuvant pelvic radiotherapy has the potential to eradicate micrometastases within the irradiated field but has not resulted in survival improvements in randomized studies. This illustrates the need for systemic therapy. Chemotherapy, mainly with anthracyclines, platinum compounds, and taxanes, renders high response rates although this unfortunately translates in only modest improvements in progression-free and overall survival. Better systemic treatments need to be developed. Investigations of the molecular mechanisms of endometrial cancer have identified possible targets for therapy. In advanced endometrial cancer one study shows that chemotherapy is better than whole abdominal radiotherapy, while in the adjuvant situation the combination of chemotherapy and radiotherapy appears promising. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/2150588
- author
- Högberg, Thomas LU
- organization
- publishing date
- 2011
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Current Oncology Reports
- volume
- 13
- pages
- 433 - 441
- publisher
- Current Science, Inc.
- external identifiers
-
- wos:000296881500003
- pmid:21874283
- scopus:81155133815
- ISSN
- 1523-3790
- DOI
- 10.1007/s11912-011-0192-x
- language
- English
- LU publication?
- yes
- id
- fb209f7e-b3de-41e0-9c95-d2b68923f635 (old id 2150588)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/21874283?dopt=Abstract
- date added to LUP
- 2016-04-04 08:52:50
- date last changed
- 2022-02-20 22:23:16
@article{fb209f7e-b3de-41e0-9c95-d2b68923f635,
abstract = {{Adjuvant pelvic radiotherapy has the potential to eradicate micrometastases within the irradiated field but has not resulted in survival improvements in randomized studies. This illustrates the need for systemic therapy. Chemotherapy, mainly with anthracyclines, platinum compounds, and taxanes, renders high response rates although this unfortunately translates in only modest improvements in progression-free and overall survival. Better systemic treatments need to be developed. Investigations of the molecular mechanisms of endometrial cancer have identified possible targets for therapy. In advanced endometrial cancer one study shows that chemotherapy is better than whole abdominal radiotherapy, while in the adjuvant situation the combination of chemotherapy and radiotherapy appears promising.}},
author = {{Högberg, Thomas}},
issn = {{1523-3790}},
language = {{eng}},
pages = {{433--441}},
publisher = {{Current Science, Inc.}},
series = {{Current Oncology Reports}},
title = {{What is the Role of Chemotherapy in Endometrial Cancer?}},
url = {{http://dx.doi.org/10.1007/s11912-011-0192-x}},
doi = {{10.1007/s11912-011-0192-x}},
volume = {{13}},
year = {{2011}},
}